[Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma].

Abstract

Targeted therapies have led to a paradigm shift in the treatment of metastatic renal cell carcinoma (mRCC). The multi-kinase inhibitor Sunitinib was rapidly established as a new standard in first-line therapy. Sunitinib was systematically developed in a comprehensive study program starting with phase II studies in second-line therapy, progressing to a phase… (More)
DOI: 10.1159/000265689

Topics

  • Presentations referencing similar topics